Expediting allogeneic cell therapies at every stage

Expediting allogeneic cell therapies at every stage

At Cellistic, we’re building an iPSCs-based platform engineered to propel allogeneic cell therapies to clinic with high efficiency and acuity at every step. From initial setup and lineage specification to proof-of-concepts through scale-up and GMP manufacturing, every capability and emerging technology at Cellistic is centered on positioning your cell therapy for success.

By establishing a GMP-like environment even in early R&D stages, we can maintain a sharp focus on your ultimate goals – IND and NDA approvals – all while delivering effectively on the complex scientific tasks directly at hand. 

Cellistic_Our_approach_S2_blob-300x217

The iPSC insights, expertise and experience from the Cellistic team are ready to
help your team pursuit successful cell therapies, by overcoming the primary challenges developers face: 

most effective way

They’re seeking the most effective way to advance their therapy

looking for a partner

They’re looking for a partner that has more than just a basic understanding of iPSCs

future scale-up

They want to be ideally positioned to maximize the efficiency of a future scale-up

Take A First Step

If current trendlines are any indication, cell therapy – and allogeneic cell therapy, more specifically – will be dominating discussions about industry innovation for years to come. More immediately, there’s another discussion that we think could prove equally interesting: One between your team and ours about how our approach to delivering on the promise of iPSCs can yield value for your science. Let’s get started here.